An exception was the study conducted by Schwartz et al. (2013), which assessed pre- and post-treatment tumor expression levels of IGF-1R, pAkt, and pS6 from patients with diverse sarcoma subtypes treated with cixutumumab/temsirolimus. This evidence concerns the gene IGF1R and sarcoma.